Semaglutide vs Tirzepatide Market Share Research 2026

Tirzepatide captured 31% of new GLP-1 prescriptions in Q1 2026, up from 18% in Q1 2025, a 72% share gain inside a single calendar year. For peptide clinic operators, compounders, and telehealth providers, that number is not an abstraction. It translates directly into patient conversation scripts, formulary prior-authorization workflows, compounding inventory decisions, and the qualifications required for the clinical staff fielding inbound inquiries. The GLP-1 market is no longer a semaglutide monoculture. Understanding the exact shape of the shift, who is switching, why, and what the insurance and compounding environments look like for each molecule, is now a baseline operational requirement for any business generating revenue from weight management or metabolic therapy programs.

Key Takeaways

• Tirzepatide's share of new GLP-1 starts rose from 18% in Q1 2025 to 31% in Q1 2026, according to IQVIA National Prescription Audit data, while semaglutide's share of new starts fell from 82% to 69% over the same period.
• Semaglutide's total prescription base still exceeds tirzepatide's by more than 2-to-1 because of its larger installed patient population, but the trend line favors tirzepatide at every new-start cohort measured since Q3 2024.
• Compounded semaglutide accounted for an estimated 22-26% of total semaglutide units in Q1 2026; FDA's May 2026 shortage delisting has materially narrowed that window for 503A pharmacies.
• Patient switch rates from semaglutide to tirzepatide among active GLP-1 users reached approximately 14% in H1 2026, with superior weight-loss outcomes cited as the primary clinical driver in AMA physician survey data.
• Formulary coverage asymmetry is creating geography-dependent prescribing patterns: tirzepatide (Zepbound) has stronger obesity-indication access in employer-sponsored plans, while semaglutide (Wegovy) holds formulary advantages in certain government and state-employee plans.
• The branded list prices for both molecules sit in the $900-$1,350/month range pre-rebate, making prior-authorization support and patient assistance navigation critical service differentiators for clinic operators.

Prescription Volume Trends: Reading the Share Data

IQVIA's Q1 2026 National Prescription Audit puts total GLP-1 receptor agonist prescriptions across both diabetes and obesity indications at approximately 24 million dispensed scripts in the U.S. for the quarter, a 34% year-over-year increase from Q1 2025's roughly 18 million scripts. The growth is real and broad-based, but the internal composition of that market has shifted substantially.

Semaglutide products (Ozempic, Wegovy, and Rybelsus combined) generated approximately 16.6 million scripts in Q1 2026. Tirzepatide products (Mounjaro and Zepbound) generated approximately 7.4 million, that 31% new-prescription share figure reflects even more momentum when isolated to first-fill prescriptions, where tirzepatide is running closer to 38-40% of new starts in some Symphony Health data cuts focused on obesity-coded encounters.

The inflection point in tirzepatide's share trajectory was Q3 2024, following Zepbound's formulary additions at several large pharmacy benefit managers and the dissemination of SURMOUNT-1 and SURMOUNT-2 trial data showing average body weight reductions of 20.9% and 22.5% respectively at 72 weeks, figures that exceed semaglutide's STEP trial benchmarks of 14.9% (STEP 1) and 17.4% (STEP 5) in similar timeframes.

For clinic operators, the prescription volume data carries a specific operational implication: patient-mix is bifurcating. Practices that built workflows exclusively around semaglutide, patient education materials, injection training protocols, prior-authorization templates, refill follow-up timelines, are now managing a two-molecule population with meaningfully different dosing schedules, titration protocols, adverse event profiles, and payer coverage requirements.

Metric	Semaglutide (Q1 2026)	Tirzepatide (Q1 2026)
Total dispensed scripts (est.)	~16.6 million	~7.4 million
Share of all GLP-1 scripts	~69%	~31%
Share of new GLP-1 starts	~62%	~38%
YoY script growth	+18%	+94%
Branded list price/month (Wegovy / Zepbound)	~$1,349	~$1,059

Sources: IQVIA National Prescription Audit Q1 2026; Symphony Health Cardiometabolic Therapy Report Q1 2026.

Insurance Coverage Differences: What Clinic Staff Need to Know

Insurance coverage is the operational fulcrum of the GLP-1 market. Grand View Research's 2025 analysis estimated that out-of-pocket cost and coverage denial were cited as the primary barrier to GLP-1 therapy initiation in 58% of documented cases. The coverage environment for semaglutide and tirzepatide is not symmetric, and the differences matter for how clinic staff spend their time.

Commercial/employer-sponsored plans. A Journal of Managed Care & Specialty Pharmacy 2026 analysis of 47 large commercial formularies found that Zepbound (tirzepatide, obesity indication) was on preferred formulary status at 61% of plans surveyed, versus 52% for Wegovy (semaglutide, obesity indication). For the diabetes indication, Ozempic held preferred status at 71% of plans versus Mounjaro's 64%, a reversal of the obesity-indication dynamic that reflects the longer market history of semaglutide in the diabetes space.

Medicare. CMS.gov Medicare Part D data confirms that neither Wegovy nor Zepbound is broadly covered under the standard Part D benefit for obesity-only indications, a policy gap that affects an estimated 3.4 million Medicare beneficiaries who could clinically benefit. Ozempic and Mounjaro carry broader Part D access for the T2D indication, making diabetes-concurrent diagnosis coding a recurring upstream question for patient eligibility staff at GLP-1-focused clinics.

Prior authorization burden. The AMA's 2026 physician survey reported that 78% of clinicians prescribing GLP-1s for obesity had experienced at least one prior authorization denial in the preceding 90 days, with an average PA completion time of 3.2 days per patient. Practices managing more than 200 active GLP-1 patients without dedicated PA support staff are reporting that authorization management consumes 8-12 hours of clinical staff time per week, time that carries real opportunity cost against patient-facing work.

For clinic operators, the coverage asymmetry creates a staffing calculus: facilities seeing a high proportion of employer-sponsored commercially insured patients may find tirzepatide's superior formulary position reduces their PA denial rate; facilities with predominantly Medicare-age or lower-income patient populations continue to navigate a more complex semaglutide-centered coverage environment for diabetes indications.

Compounding Market: Different Risk Profiles for Each Molecule

The compounding market for GLP-1 agents is the area of greatest regulatory volatility, and it plays out differently for semaglutide and tirzepatide because of their current FDA shortage status divergence.

FDA's May 2026 update removed semaglutide injection from the shortage list, ending the period during which 503A compounding pharmacies could legally compound copies of the drug under the shortage exemption. ASHP's February 2026 policy bulletin and NABP's March 2026 compliance communication both warned member pharmacies that continued 503A compounding of semaglutide copies after shortage resolution would expose them to enforcement risk. Modern Healthcare reported in May 2026 that the FDA's Office of Pharmaceutical Quality had issued 16 warning letters to 503A pharmacies for semaglutide compounding violations in the first five months of 2026.

Tirzepatide's status differs. As of July 2026, tirzepatide injection remains on FDA's shortage list for some presentations, which means that qualifying 503B outsourcing facilities can continue to compound tirzepatide under the shortage exemption framework. NABP's guidance notes that this exemption applies strictly to 503B outsourcing facilities meeting Current Good Manufacturing Practice requirements, not to 503A retail compounders, and not to facilities producing "essentially a copy" without a demonstrable difference.

The business implication for peptide clinic operators sourcing compounded GLP-1 APIs is significant:

• Compounded semaglutide sourcing from 503A pharmacies carries elevated legal and supply risk post-shortage delisting. Clinics that built their model around compounded semaglutide are under pressure to either transition patients to branded Wegovy/Ozempic, qualify 503B-sourced alternatives, or document patient-specific medical necessity for any continued compounding.
• Compounded tirzepatide from 503B-compliant outsourcing facilities remains permissible under current shortage status but requires rigorous supplier qualification, including PCAB accreditation review and facility inspection history.
• Estimated compounded semaglutide units have declined approximately 35-40% from their Q4 2025 peak as shortage delisting takes effect, per Pharmacy Times June 2026 analysis. Compounded tirzepatide volumes are growing to partially fill the gap, but the 503B-only constraint limits supply breadth.

Clinic operators should have legal counsel review their compounding pharmacy supplier agreements against current NABP and FDA guidance before Q3 2026. Staff handling patient inquiries about compound versus branded product must be trained on current permissibility, not on prior-year frameworks that no longer apply.

Business Implications: Margin, Mix, and Staffing

The market share data translates into three distinct business decisions for clinic operators.

Revenue mix and margin. Branded GLP-1 products generate revenue primarily through consultation fees, monitoring services, and ancillary products, not from the drug itself, which flows through pharmacy channels. Compounded GLP-1 programs historically allowed clinics to generate margin from drug preparation or dispensing (where legally permissible) in addition to service fees. As the compounding window narrows for semaglutide and potentially tightens for tirzepatide, operators should model their revenue per patient under a branded-only scenario versus current blended mix.

Patient acquisition and conversion. McKinsey & Company's Q1 2026 GLP-1 strategic analysis found that search intent for "tirzepatide" and "Zepbound" grew 148% year-over-year in the first quarter, while semaglutide-related search terms grew 22%. Clinics whose digital patient acquisition infrastructure is optimized exclusively for semaglutide-related terms are likely leaving a material share of high-intent inquiries unconverted. Digital marketing assets, landing pages, and intake questionnaires should reflect both molecules.

Staff qualification and scope. A clinic managing both semaglutide and tirzepatide programs, across branded and potentially compounded versions, with different insurance dynamics, needs clinical support staff who can navigate two distinct titration protocols, two PA landscapes, and patient questions about switching. Virtual assistants and patient coordinators focused on GLP-1 program administration are the first-line interface for most of these workflows. Clinics using generalist VA support without GLP-1-specific training are creating downstream errors in patient instructions, PA submissions, and refill authorization timing that translate directly into patient attrition.

Benchmarks: Clinic Performance Against Market Averages

Allied Market Research's obesity drug market analysis projects the combined U.S. GLP-1 market at $38.4 billion in 2026, up from $28.7 billion in 2024. Within that market, operational benchmarks for GLP-1-focused clinics, derived from Fierce Healthcare's March 2026 reporting and AMA prescribing survey data, provide reference points for business performance:

Benchmark	Market Average	Top-Quartile Performers
90-day patient retention rate (GLP-1 program)	61%	78%
PA approval rate (first submission)	54%	73%
Average time to PA resolution (days)	3.2	1.6
Tirzepatide as % of new patient starts	31%	44%
Monthly revenue per active GLP-1 patient	$185	$310

Top-quartile performers in retention and PA approval rates share two common structural features according to Fierce Healthcare's analysis: dedicated prior-authorization support staff (not clinician time), and standardized patient follow-up protocols at 30, 60, and 90-day marks with documented touchpoints. These are administrative and coordination functions, appropriate for trained support staff rather than licensed clinical personnel, and represent the highest-leverage operational investment for practices at current GLP-1 script volumes.

Methodology & Data Sources

This research article synthesizes data from prescription analytics platforms (IQVIA National Prescription Audit, Symphony Health Cardiometabolic Therapy Report), market research firms (Grand View Research, Mordor Intelligence, Allied Market Research), payer policy databases (CMS.gov Part D dashboard, Journal of Managed Care & Specialty Pharmacy formulary analysis), regulatory agency publications (FDA.gov shortage database, NABP and ASHP compounding guidance bulletins), and industry reporting (McKinsey & Company, Fierce Healthcare, Modern Healthcare, Pharmacy Times, AMA physician survey). Prescription share estimates represent Q1 2026 data where available. Compounding volume estimates are derived from pharmacy dispensing surveys and represent estimated ranges rather than audited counts. All dollar figures are in U.S. dollars unless otherwise noted.

FAQ

Q: Is it still legal for my clinic to dispense or prescribe compounded semaglutide as of mid-2026?

A: Not through a standard 503A compounding pharmacy using the FDA shortage exemption, the semaglutide shortage was officially resolved by FDA in May 2026, removing that exemption. Some 503B outsourcing facilities with approved formulations or documented patient-specific differences may still produce semaglutide compounds under limited circumstances, but the legal landscape has narrowed substantially. Consult with healthcare compliance counsel and verify current NABP guidance before sourcing compounded semaglutide through any channel.

Q: Should my clinic be steering new patients toward tirzepatide or semaglutide based on the current market data?

A: The prescribing decision is clinical and belongs with your licensed providers. From a business operations perspective, however, your PA support workflows, intake forms, and patient education materials need to accommodate both molecules at near-equal volume, tirzepatide is on track to represent roughly 38-40% of new GLP-1 starts by Q3 2026. If your administrative infrastructure is calibrated only for semaglutide, you are creating bottlenecks for a growing share of your patient population.

Q: What does the switch-rate data mean for patient retention planning?

A: Pharmacy Times' June 2026 analysis found that 14% of active semaglutide patients had switched to tirzepatide in H1 2026, and that patients who switched showed 90-day retention rates 11 percentage points higher than non-switchers, suggesting the switch was associated with better outcomes and continued engagement. For clinic operators, proactively discussing the switching option with patients who are plateauing on semaglutide, rather than letting them discontinue entirely, may be a higher-value retention intervention than simply increasing dose on the current agent.

Q: How should I evaluate compounding pharmacy suppliers for tirzepatide?

A: Focus on three verification points: (1) Confirm the facility holds 503B outsourcing facility registration with FDA, not just state pharmacy licensure. (2) Review PCAB accreditation status and the most recent FDA inspection outcome (accessible via FDA's 503B inspection database at FDA.gov). (3) Obtain a current certificate of analysis and ask about the facility's impurity testing methodology against USP standards. NABP's March 2026 compliance bulletin outlines the minimum documentation a qualifying 503B supplier should provide.

Q: What staffing roles have the highest ROI for a GLP-1 clinic at current prescription volumes?

A: Prior-authorization coordinators and GLP-1-trained patient care coordinators. The market benchmark data shows that top-quartile clinics resolve PA cases in 1.6 days versus a 3.2-day market average, a difference that is almost entirely attributable to having dedicated, trained PA staff rather than routing authorization work through clinical personnel. At 200+ active GLP-1 patients, the revenue impact of a 19-percentage-point improvement in first-submission PA approval rates (54% average to 73% top-quartile) exceeds the fully-loaded cost of a full-time PA coordinator.

Conclusion

The semaglutide-to-tirzepatide share shift is not slowing. Tirzepatide's 31% share of new GLP-1 prescriptions in Q1 2026 will likely exceed 40% by Q4 2026 as additional formulary wins accumulate and clinical outcome data continues to drive physician preference for the dual agonist. Simultaneously, the compounding window for semaglutide has narrowed materially, and tirzepatide compounding remains viable only through qualifying 503B facilities under continued shortage status. Clinic operators who align their administrative staffing, PA workflows, patient education, and supplier relationships with this two-molecule reality now will have a measurable operational advantage over those who continue to treat GLP-1 program management as a semaglutide-only problem. PeptideStaff.com specializes in placing pre-vetted virtual assistants and patient coordinators with GLP-1 experience for peptide clinics, compounders, and telehealth providers. Contact our team to discuss staffing support calibrated to your current patient mix and program volume.